The Challenge of Cheap Interventions and Expensive Clinical Trials
Key claim: Affordable candidate aging interventions (from senolytics and rapamycin to FMT and HBOT) may justify widespread use but remain under-validated because rigorous clinical trials are disproportionately expensive relative to the interventions themselves.
Abstract
There are a good many affordable interventions that may well produce enough of an effect on aging to justify widespread use. At the more compelling end of the spectrum, based on a relatively large effect size in animal data and very limited supporting human data, we might consider the senolytic combination of dasatinib and quercetin, stem cell and exosome therapies, and fecal microbiota transplantation from a young donor to an old recipient. Somewhere in the middle lies rapamycin and some bisphosphonate therapies for osteoporosis. At the less compelling end of the list, based on an expectation of smaller positive outcomes and very mixed data for any effect on aging, we find widely used interventions such as hyperbaric oxygen therapy. But we don’t know with reasonable […]
Why this matters
Affordable candidate aging interventions (from senolytics and rapamycin to FMT and HBOT) may justify widespread use but remain under-validated because rigorous clinical trials are disproportionately expensive relative to the interventions themselves.